LAWRENCEVILLE, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and…
-CLIMB-111 and CLIMB-121 fully enrolled; completed regulatory discussions for exagamglogene autotemcel (exa-cel), formerly known as CTX001™, with the European Medicines…
— MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy — —…
Second quarter revenues of €3.2 billion1, net profit of €1.7 billion and fully diluted earnings per share of €6.45 ($6.872) as well…
Data from the Phase 3 SPIRIT program showed MYFEMBREE reduced menstrual pain and non-menstrual pelvic pain in premenopausal women with…
IRVINE, Calif., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet…
MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, Aug. 03, 2022 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk”…
BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the…
Updates on Recent Transaction and Business will be ProvidedOXNARD, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- CURE Pharmaceutical Holding Corp.…
MELBOURNE, Australia, July 28, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader…